PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetMed Express reports Q1 2023 earnings, anticipates growth from PetCareRx acquisition

PetMed Express faced sales decline, but the acquisition of PetCareRx and strong new customer growth provide optimism for future profitability. Financial stability, operational focus, and strategic partnerships position the company for long-term success.

PetMed Express reports Q3 sales dip but gains new customers

PetMed Express navigated challenges with a 3% decrease in YoY sales but gained 9% more net new customers. The company's focus on pet health expertise and expanding offerings positions it for future growth.
Despite advertising spending increases, PetMed maintains a strong balance sheet with over $102 million in unrestricted cash. Management's confidence in future prospects and innovative strategies bode well for the company's growth trajectory.

PetMed Express reports sales decline, eyes growth from acquisitions

PetMed Express focused on pet wellness, recent acquisitions, and strategic investments in telemedicine and pet insurance.
Despite sales decline in fiscal year 2023, the company aims for growth from the PetCareRx acquisition in 2024.
Challenges in over-the-counter medication sales and a net loss in Q4 were offset by a strong cash position and strategic focus on growth.

PetMed Express reports record revenue growth and expands pet insurance

PetMed Express (PETS) demonstrated strong financial performance in Q1 2024, with record-setting revenue growth and a focus on sustainable long-term growth.
The company's strategic initiatives, including the integration of the PetCareRx acquisition and expansion into the pet insurance market, position it for future success.
While facing challenges in a competitive market, PetMed Express has opportunities to solidify its market leadership in pet wellness and healthcare through customer-centric strategies.

PetMed Express reports Q2 growth, shifts focus to tech investments

PetMed Express (PETS) demonstrated solid financial performance in Q2 2024 with revenue growth and operational enhancements. While facing challenges in customer retention and market conditions, the company is strategically investing in technology and growth initiatives. With a focus on long-term sustainability and innovation, PetMed Express aims to drive growth and shareholder value in the pet health sector.

PetMed Express reports strong sales growth amidst accounting challenges

PetMed Express shows resilience in sales growth despite accounting challenges.
The company's focus on transparency and customer programs is a key strength.
Challenges include the need for a financial restatement and maintaining investor confidence.
Opportunities lie in strengthening internal controls and driving growth through acquisitions.

PetMed Express reports sales growth, invests in tech for future

PetMed Express (PETS) reported positive sales growth in Q4 2024 driven by the PetCareRx acquisition, despite a net loss due to acquisition-related expenses.
The company's customer-centric focus, strategic investments in technology, and strong leadership team additions position it well for future growth.
Challenges include managing expenses post-acquisition and navigating competitive pressures in the pet medications market, while opportunities exist in market expansion and operational enhancements.

PetMed Express (PETS) reports Q1 challenges but sees early improvements

PetMed Express (PETS) navigated a transition quarter with a focus on growth and profitability. Despite a sales decline and margin decrease, early signs of improvement were observed. The company emphasized optimizing cost structure, enhancing customer growth strategies, and implementing technology improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetMed Express, Inc. provides markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, and generic substitutes. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

PetMed Express' (PETS) Management on Q1 2021 Results - Earnings Call Transcript

PetMed Express Inc (NASDAQ: PETS) has reported a Q1 EPS of $0.22, lagging the consensus of 0.36 and lower than $0.39 posted a year ago. Net sales were $79.3 million, down 18% Y/Y and far below the consensus estimate of $86.5 million.

PetMed Stock Falls As Q1 Earnings Trail Analyst Consensus, Operating Margin Contraction

PetMed Express Inc. shares slumped 11% in Monday premarket trading after the pet pharmacy company announced first-quarter earnings and sales that missed Street expectations. Net income totaled $4.4 million, or 22 cents per share, down from $7.8 million, or 39 cents per share, last year.

PetMed Express says advertising ineffectiveness played a role in earnings and sales miss

DELRAY BEACH, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2021. Net sales for the quarter ended June 30, 2021 were $79.3 million, compared to $96.2 million for the quarter ended June 30, 2020, but relatively flat versus the quarter ended June 30, 2019, prior to the pandemic. Net income for the quarter ended June 30, 2021 was $4.4 million, or $0.22 diluted per share, compared to net income of $7.8 million, or $0.39 diluted per share, for the same quarter the prior year, and $5.3 million or $0.26 for the quarter ended June 30, 2019. During the quarter ended June 30, 2021 there were one-time charges of $717,000 related to the CEO's separation agreement. The Company also incurred an additional cost of $260,000 related to brand and marketing consulting fees.

PetMed Express, Inc. d/b/a 1-800-PetMeds Announces Its First Quarter Financial Results and a Quarterly Dividend of $0.30 Per Share

DELRAY BEACH, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended June 30, 2021 on Monday, July 26, 2021 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, the Company will host a conference call to review the financial results.

PetMed Express d/b/a 1-800-PetMeds to Announce Its First Quarter Financial Results on July 26, 2021

PETS yields 3.84% - it's the highest yield by far in the pet industry - and has no debt. It also has very high yield options available - two trades are included in this article.

PetMed Express: Top Dog For Pet Dividends - Pet Industry Review

PetMed Express, Inc. (NASDAQ:PETS) is an online pet pharmacy based in the United States, delivering pet medications and other health products for dogs, cats, and horses.

PetMed Express Stock: Prioritizing Consistency Over Growth

A. O. Smith

Hormel Foods

As a dividend growth investor, I focus on finding and owning the most financially sound companies in the market that I can. Those companies in a very stable financial position tend to be those that are well run and maintain an advantageous industry positioning, which allows for the possibility of a growing dividend.

3 Companies With Exceptional Financial Strength

Colgate-Palmolive

General Mills

These three pet stocks will help investors cash in on dividends amidst the growing pet care sector. Here's what you need to know.

3 Pet Stocks for Growth and Dividends

PetMed Express's share price has, in recent months, been beaten down by about 50%.

PetMed Express: A Safe Dividend, But Lacks A Margin Of Safety

AMC Entertainment

BlackBerry

Bed Bath & Beyond

GameStop

Nikola

Nokia

Pennsylvania Real Estate Investment Trust

Palantir Technologies

SNDL Inc.

Tilray Brands

Through creating retail investor interest on platforms like Facebook, Reddit, and Robinhood, certain companies have seen massive surges in share prices and volumes.

12 Reddit Stocks To Watch Right Now

These 2 Nasdaq Meme Stocks Crashed Back to Earth Thursday

An analyst's downgrade zapped some of Wednesday's momentum.

Why PetMed Express Stock Is Sinking Today

A surge in meme stocks and a short squeeze sent the online pet pharmacy soaring.

Why Petmed Express Stock Skyrocketed Today

Today, short squeeze interest is driving the stock prices of heavily shorted stocks such as PETS stock dramatically higher on high volume. The post PETS Stock: 9 Things to Know About Short-Squeeze Play PetMed Express appeared first on InvestorPlace.

PETS Stock: 9 Things to Know About Short-Squeeze Play PetMed Express

Boqii Holding

Chewy

Freshpet

PetIQ

Trupanion

Petco Health and Wellness

Zoetis

While the market has taken a beating over recent days, pullbacks are the mother's milk of effective investment strategies, and shrewd market participants will already have a growing shopping list on hand. With that in mind, one area that may deserve special attention and offer outsized potential ahead is the pet care space.

Growth Stock Spotlight: Acquisition Pits CSOC as Fresh Option in Booming Petcare Market

The reopening of veterinary clinics and pet retailers caused lower sales for the online pet pharmacy.

What's Behind PetMed Express' Disappointing Q4 Results

Express

PetMed Express, Inc. (PETS) CEO Menderes Akdag on Q4 2020 Results - Earnings Call Transcript

Shares of PetMed Express (NASDAQ:PETS) moved higher by 1.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 2.86% over the past year to $0.34, which missed the estimate of $0.40.

Recap: PetMed Express Q4 Earnings

8.8% Increase in Fiscal 2021 Sales 18.4% Increase in Fiscal 2021 Net Income 9.7% Increase in Fiscal 2021 Reorder Sales

PetMed Express, Inc. d/b/a 1-800-PetMeds Announces Its Fourth Quarter and Fiscal Year End Financial Results and Increases Its Quarterly Dividend to $0.30 per Share

Northrop Grumman

Big Increases Expected In May From Northrop Grumman, PetMed Express

On Monday, May 03, PetMed Express (NASDAQ:PETS) will release its latest earnings report. Decipher the announcement with Benzinga's help.

A Preview Of PetMed Express's Earnings

DELRAY BEACH, Fla., April 26, 2021 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the fiscal year ended March 31, 2021 on Monday, May 3, 2021 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, Menderes Akdag, the Company's Chief Executive Officer and President, will host a conference call to review the financial results.

PetMed Express d/b/a 1-800-PetMeds to Announce Its Fiscal Year End Financial Results on May 3, 2021

Elanco Animal Health Inc

Northern Star Acquisition Corp

Not all pet companies are created equal. These pet stocks are positioned for upside as the industry witnesses steady growth.

7 Pet Stocks That Make Good Long-Term Holdings

The company offers a brilliant combination of growth and value.

News for PetMed Express Stock (PETS)